Side-by-side · Research reference

AdipotidevsIpamorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED15/49 cited

BPhase 1HUMAN-REVIEWED21/57 cited

Adipotide

Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only

PreclinicalStatus

PHB1TargetHossen 2013

ApoptosisMechanismHossen 2013

IV · Systemic · Preclinical Protocols OnlyHossen 2013

Ipamorelin

Selective GHRP · Ghrelin Mimetic

200–300 mcgPer doseRaun 1998

Phase 1Evidence levelRaun 1998 Sigalos 2018

~2 hrHalf-lifeRaun 1998

SQ · Multiple sites · 1–3×/day

01Mechanism of Action

Parameter

Adipotide

Ipamorelin

Primary target

Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013

Ghrelin receptor (GHS-R1a) on anterior pituitaryRaun 1998

Pathway

CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption

GHS-R1a binding → Gαq/11 → ↑intracellular Ca²⁺ → GH vesicle exocytosisRaun 1998 Bowers 1991

Downstream effect

Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss

GH pulse amplification, IGF-1 elevation, recovery and lipolytic effectsBowers 2002

Feedback intact?

N/A — Direct apoptotic mechanism, non-hormonal

Yes — pulsatile pattern preserved; somatostatin feedback activeBowers 2002

Origin

Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence

Pentapeptide H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂; rationally designed for ghrelin-receptor selectivityRaun 1998

Antibody development

—

Not reported in short-term studies

02Dosage Protocols

Parameter

Adipotide

Ipamorelin

Animal dose (mouse)

Low dose (not specified in abstract)Hossen 2013

Systemic injection in diet-induced obesity (DIO) models.Hossen 2013

—

Route

Intravenous (systemic injection)

—

Frequency

Not specified in available data

1–3× per day

Once daily pre-sleep is most common; twice or thrice for advanced users.

Evidence basis

Preclinical animal models only

Phase 1 + clinical practiceRaun 1998 Sigalos 2018

Human data

None — no clinical trials reported

—

Standard dose

—

200–300 mcg per injectionRaun 1998

Anecdotal community range; clinical doses 1–3 mg IV in trials.

Lower / starter dose

—

100 mcg per dose

Duration

—

8–12 weeks on / 4 weeks off (anecdotal)

GHS-R desensitisation reported with continuous dosing.

Reconstitution

—

Bacteriostatic water; typical 2 mL per 5 mg vial

Timing

—

Pre-sleep + fasted preferred; 30 min away from food

Half-life

—

~2 hoursRaun 1998

Longer than GHRP-6 (15 min); shorter than CJC-1295-DAC (~8 days).

03Metabolic / Fat Loss Evidence

Parameter

Adipotide

Ipamorelin

Primary fat target

White adipose tissue (all depots)

—

Mechanism

Vascular apoptosis → adipose blood supply collapse → adipocyte deathHossen 2013

—

Body weight reduction

Significant reduction in DIO miceHossen 2013

Absolute values not provided in abstract.

—

Leptin levels

Significant decrease

Parallel to adipose mass reduction.

—

Effect on adipocytes

Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013

—

Ectopic fat

Reduction in ectopic fat depositionHossen 2013

Marker of dysfunctional adipose tissue / metabolic syndrome.

—

Species tested

Obese rhesus monkeys, DIO mice

—

Human translation

Unknown — no clinical trials

—

04Side Effects & Safety

Parameter

Adipotide

Ipamorelin

Safety profile

Unknown — preclinical data only

—

Vascular selectivity

Targets adipose vasculature; off-target vascular effects unknown

—

Apoptotic mechanism risk

Pro-apoptotic payload may affect unintended tissues if selectivity incomplete

—

Kidney / liver toxicity

Not reported in available data

—

Immunogenicity

Not assessed in available data

—

Cortisol elevation

—

Negligible vs other GHRPsRaun 1998

Prolactin elevation

—

NegligibleRaun 1998

Hunger

—

Mild appetite increase via ghrelin-receptor crosstalk

Injection site reaction

—

Mild irritation possible

GH excess (overdose)

—

Joint pain, edema, insulin resistance

IGF-1 elevation

—

Dose-dependent; monitor with chronic high-dose use

Cancer risk

—

Theoretical via GH/IGF-1 axis; contraindicated in active malignancy

Pregnancy / OB

—

Avoid

Absolute Contraindications

Adipotide

·Human use — not approved, no clinical safety data

Ipamorelin

·Active malignancy or cancer history
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Relative Contraindications

Adipotide

·Any condition requiring intact adipose-tissue vascularisation

Ipamorelin

·Untreated diabetes
·Severe insulin resistance
·Concurrent corticosteroid use (theoretical desensitisation)

05Administration Protocol

Parameter

Adipotide

Ipamorelin

1. Route

Intravenous injection (systemic) in preclinical models. No human protocols exist.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL. Roll gently. Solution should be clear.

2. Formulation

Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013

Subcutaneous, abdomen or thigh. Rotate sites. Pinch fat for shallow SQ delivery.

3. Preclinical dosing

Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013

Pre-sleep optimal — aligns with natural GH pulse. Some protocols add a morning fasted dose.

4. Storage

Not specified — likely requires peptide-grade lyophilised storage and reconstitution.

Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.

5. Needle

—

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Adipotide

— no documented stacks

Ipamorelin

+ Tesamorelin

Strong

View Tesamorelin →

Ipamorelin (GHRP) + tesamorelin (GHRH analogue) is the textbook dual-axis GH stack. They activate two distinct pituitary receptors — the ghrelin receptor and the GHRH receptor — producing a synergistic GH pulse larger than either alone. Ipamorelin's selectivity (no cortisol/prolactin spike) makes it the ideal GHRP partner for long-term protocols.

Ipamorelin: 200–300 mcg SQ · pre-sleep
Tesamorelin: 2 mg SQ · same injection · pre-sleep
Primary benefit: Maximal GH pulsatility, fat loss, recovery, sleep depth

Raun 1998 Bowers 2002

+ CJC-1295 (no DAC)

Strong

View CJC-1295 (no DAC) →

CJC-1295 (no DAC) is a short-acting GHRH analogue. Combined with ipamorelin (GHRP), the pulse is amplified across both receptor systems with timing similar to native physiology. Without the DAC modification, the stack maintains sharp peaks rather than the sustained elevation seen with CJC-1295-DAC + ipamorelin.

Ipamorelin: 200–300 mcg SQ · pre-sleep
CJC-1295 (no DAC): 100 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation matching physiological pattern

Teichman 2006 Ionescu 2006